TY - JOUR
T1 - Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors
T2 - the multicenter FAMI-L1 study
AU - Cortellini, Alessio
AU - Buti, Sebastiano
AU - Bersanelli, Melissa
AU - Giusti, Raffaele
AU - Perrone, Fabiana
AU - Di Marino, Pietro
AU - Tinari, Nicola
AU - De Tursi, Michele
AU - Grassadonia, Antonino
AU - Cannita, Katia
AU - Tessitore, Alessandra
AU - Zoratto, Federica
AU - Veltri, Enzo
AU - Malorgio, Francesco
AU - Russano, Marco
AU - Anesi, Cecilia
AU - Zeppola, Tea
AU - Filetti, Marco
AU - Marchetti, Paolo
AU - Botticelli, Andrea
AU - Cappellini, Gian Carlo Antonini
AU - De Galitiis, Federica
AU - Vitale, Maria Giuseppa
AU - Rastelli, Francesca
AU - Pergolesi, Federica
AU - Berardi, Rossana
AU - Rinaldi, Silvia
AU - Tudini, Marianna
AU - Silva, Rosa Rita
AU - Pireddu, Annagrazia
AU - Atzori, Francesco
AU - Iacono, Daniela
AU - Migliorino, Maria Rita
AU - Gelibter, Alain
AU - Occhipinti, Mario Alberto
AU - Martella, Francesco
AU - Inno, Alessandro
AU - Gori, Stefania
AU - Bracarda, Sergio
AU - Zannori, Cristina
AU - Mosillo, Claudia
AU - Parisi, Alessandro
AU - Porzio, Giampiero
AU - Mallardo, Domenico
AU - Fargnoli, Maria Concetta
AU - Tiseo, Marcello
AU - Santini, Daniele
AU - Ascierto, Paolo A
AU - Ficorella, Corrado
N1 - © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2020
Y1 - 2020
N2 - Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48-0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39-0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors.
AB - Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48-0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39-0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors.
U2 - 10.1080/2162402X.2019.1710389
DO - 10.1080/2162402X.2019.1710389
M3 - Article
C2 - 32002308
VL - 9
SP - 1710389
JO - OncoImmunology
JF - OncoImmunology
SN - 2162-4011
IS - 1
ER -